

# Contents

<b>1 Introduction on Cancer Immunology and Immunotherapy</b>	<b>1</b>
Nima Rezaei, Seyed Hossein Aalaei-Andabili, and Howard L. Kaufman	
1.1 Introduction	1
1.2 Cancer Immunity	2
1.3 Cancer and Immune System Impairment	3
1.4 Immune System Reaction to Cancer	3
1.5 Genetic and Environmental Carcinogenesis	4
1.5.1 Cancer Cells Escape from Host Immunosurveillance	4
1.5.2 Cancer Immunodiagnosis	4
1.6 Cancer Treatment	5
1.6.1 Cancer Immunotherapy	5
1.6.2 Cancer Cell “Switch”	6
1.7 Concluding Remarks	6
References	7
<b>2 Inflammatory and Innate Immune Cells in Cancer Microenvironment and Progression</b>	<b>9</b>
Patrick Brennecke, Paola Allavena, Ilaria Laface, Alberto Mantovani, and Barbara Bottazzi	
2.1 Introduction	9
2.2 Heterogeneity of Myeloid Cells in the Tumor Microenvironment	10
2.2.1 Myeloid Subsets in the Tumor Microenvironment	10
2.2.2 Recruitment of Myeloid Cells in Tumors	12
2.2.3 Tumor-Derived Factors Affecting Myeloid Differentiation and Polarized Functions	13
2.3 Pro-tumoral Functions of Tumor-Associated Myeloid Cells	13
2.3.1 Tumor Proliferation and Survival	14
2.3.2 Angiogenesis	15

2.3.3	Cancer Cell Dissemination . . . . .	16
2.3.4	Suppression of Adaptive Immunity . . . . .	18
2.4	Selected Aspects of Therapeutic Targeting of TAMC . . . . .	19
2.5	Concluding Remarks . . . . .	20
	References . . . . .	21
<b>3</b>	<b>Role of Innate Immunity in Cancers and Antitumor Response . . . . .</b>	<b>29</b>
	Masahisa Jinushi and Muhammad Baghdadi	
3.1	Introduction . . . . .	29
3.2	Role of Innate Immune Cells in Cancer and Antitumor Immunity . . . . .	30
3.2.1	Natural Killer (NK) Cells . . . . .	30
3.2.2	Natural Killer T (NKT) Cells . . . . .	31
3.2.3	$\gamma\delta$ -T Cells . . . . .	31
3.2.4	Macrophages . . . . .	31
3.2.5	Dendritic Cells . . . . .	32
3.2.6	Granulocytes . . . . .	32
3.3	The Role of Innate Immune Receptors on Innate Immune Cells in Cancer and Antitumor Immunity . . . . .	32
3.3.1	Toll-Like Receptors (TLRs) . . . . .	32
3.3.2	RIG-I-Like Helicases (RLHs) . . . . .	33
3.3.3	NOD-Like Receptors (NLRs) . . . . .	33
3.3.4	Phagocytosis Receptors . . . . .	33
3.3.5	C-Type Lectin-Like Receptors (CLRs) . . . . .	34
3.3.6	NK Cell Receptors . . . . .	34
3.3.7	B7 Family . . . . .	37
3.4	The Role of Effectors Produced from Innate Immune Cells in Cancer and Antitumor Immunity . . . . .	37
3.4.1	Interferons (IFNs) . . . . .	37
3.4.2	Other Cytokines . . . . .	38
3.4.3	Chemokines . . . . .	39
3.5	Concluding Remarks . . . . .	40
	References . . . . .	40
<b>4</b>	<b>B Cells in Cancer Immunology: For or Against Cancer Growth? . . . . .</b>	<b>47</b>
	Qiao Li, Qin Pan, Huimin Tao, Xiao-Lian Zhang, Shiang Huang, and Alfred E. Chang	
4.1	Introduction . . . . .	48
4.2	CD40-Activated B (CD40-B) Cells . . . . .	48
4.3	Tumor Killer B Cells . . . . .	50
4.4	Tumor-Infiltrating B Cells (TIL-Bs) in Cancer . . . . .	52
4.5	Resting B Cells and Regulatory B Cells in Cancer . . . . .	53
4.6	Concluding Remarks . . . . .	55
	References . . . . .	57

<b>5 The Role of Exhaustion in Tumor-Induced T Cell Dysfunction in Cancer</b>	<b>61</b>
Heriberto Prado-Garcia, Susana Romero-Garcia, and Jose Sullivan Lopez-Gonzalez	
5.1 Introduction	61
5.2 T Cell Activation	62
5.3 T Cell Anergy	63
5.3.1 T Cell Anergy in Cancer	64
5.4 T Cell Exhaustion	65
5.4.1 Mechanisms for Inducing T Cell Exhaustion	65
5.4.2 Identification of Exhausted T Cells	66
5.5 T Cell Exhaustion in Cancer	67
5.5.1 A Particular Case: T Cell Exhaustion in Lung Cancer Patients	69
5.6 Concluding Remarks	72
References	72
<b>6 Regulatory T Cells and Th17 Cells in Cancer Microenvironment</b>	<b>77</b>
Chang H. Kim	
6.1 Introduction	77
6.2 Diversity of Tumor Microenvironments and Tumor Tissue Factors	79
6.3 Generation of Tregs and Th17 Cells	80
6.4 Impact of Tumor-Derived Factors on Regulation of T-Cell Differentiation	81
6.5 Migration of Tregs and Th17 Cells into Tumors	82
6.6 Impact of Tregs and Th17 Cells on Antitumor Immune Responses	84
6.7 Concluding Remarks	85
References	86
<b>7 Role of Cytokines in Tumor Immunity and Immune Tolerance to Cancer</b>	<b>93</b>
Murugaiyan Gopal	
7.1 Introduction	93
7.2 Cytokine Regulation of the Antitumor Immune Response	94
7.2.1 IL-12	95
7.2.2 IL-27	100
7.3 Cytokines in Immune Tolerance to Cancer	101
7.3.1 TGF- $\beta$	101
7.3.2 IL-17	105
7.3.3 IL-23	108
7.3.4 IL-35	108
7.3.5 IL-10	109
7.4 Concluding Remarks	111
References	111

<b>8</b>	<b>Role of Chemokines and Chemokine Receptors in Cancer ...</b>	<b>121</b>
	Mathieu Paul Rodero, Christophe Combadière, and Alexandre Boissonnas	
8.1	Introduction .....	121
8.2	Chemokines and Chemokine Receptors .....	123
8.3	Control of Tumor Cell Behavior .....	125
8.3.1	Chemokines and Chemokine Receptor Alterations During Neoplastic Transformation .....	125
8.3.2	Metastasis/Homing .....	126
8.3.3	Senescence, Proliferation, and Survival .....	127
8.4	Control of Immune Cell Behaviors .....	128
8.4.1	Chemokines Involved in T-Cell Antitumor Immune Response .....	128
8.4.2	Chemokines in Innate Immune Components .....	130
8.4.3	Chemokine and Tumor-Induced Tolerance .....	131
8.5	Alternative Tumor-Associated Physiological Functions of Chemokines .....	132
8.5.1	Angiogenesis .....	132
8.5.2	Fibrosis and Extracellular Matrix Remodeling .....	132
8.6	Clinical Aspect .....	133
8.6.1	Prognosis .....	133
8.6.2	CC Chemokines/Chemokine Receptors .....	133
8.6.3	CXC Chemokines .....	135
8.6.4	CX3C Chemokine Receptors .....	135
8.6.5	Chemokine Circulating Expression .....	135
8.6.6	Therapeutic Strategies .....	136
8.7	Concluding Remarks .....	137
	References .....	138
<b>9</b>	<b>The CD95/CD95L Signaling Pathway: A Role in Carcinogenesis .....</b>	<b>143</b>
	Amélie Fouqué and Patrick Legembre	
9.1	Introduction .....	143
9.2	TNF Receptor Family .....	144
9.2.1	TNFR1 Signaling Pathways .....	144
9.2.2	TNF/TNFR: A Gold Mine for Therapeutic Tools ...	145
9.3	CD95: A Death Receptor? .....	146
9.3.1	Structure/Function .....	146
9.3.2	Type I/II Signaling Pathways .....	148
9.3.3	What Can We Learn from CD95 Mutations? .....	148
9.3.4	Regulation of the Initial Steps of CD95-Mediated Signaling .....	150
9.3.5	Programmed Necrosis Also Known as Necroptosis .....	152
9.3.6	CD95L, an Inflammatory/Oncogenic Cytokine? ...	152
9.4	Concluding Remarks .....	155
	References .....	156

**10 MHC Class I Molecules and Cancer Progression:  
Lessons Learned from Preclinical Mouse Models. . . . . 161**  
Irene Romero, Ignacio Algarra, and Angel M. Garcia-Lora

10.1 Introduction. . . . . 161

10.2 MHC-I Cell Surface Expression on Tumor Cells  
and Primary Tumor Growth . . . . . 162

10.2.1 Studies in GR9 Tumor Model: H-2 Antigen  
Surface Expression and Tumorigenic Capacity . . . . . 164

10.3 MHC-I Expression and Metastatic Progression . . . . . 166

10.3.1 MHC Class I Expression on Primary  
Tumor Cells May Determine Spontaneous  
Metastatic Capacity. . . . . 166

10.3.2 Different MHC-I Surface Expression on GR9  
Tumor Clones Determines Their Spontaneous  
Metastatic Capacity. . . . . 167

10.4 Immunotherapy as a Treatment Against Cancers  
Expressing Different MHC-I Surface Expression. . . . . 169

10.4.1 Immunotherapy as a Treatment Against  
Primary Tumors with Different Levels of  
MHC-I Expression . . . . . 169

10.4.2 Immunotherapy as a Treatment Against  
Metastatic Progression Derived from Primary  
Tumors with Different MHC-I Expression . . . . . 170

10.5 Concluding Remarks. . . . . 170

References . . . . . 171

**11 Role of Plasmacytoid Dendritic Cells in Cancer . . . . . 177**  
Michela Terlizzi, Aldo Pinto, and Rosalinda Sorrentino

11.1 Introduction. . . . . 177

11.2 Localization and Trafficking Patterns of Plasmacytoid  
Dendritic Cells (pDCs) . . . . . 178

11.3 Plasmacytoid Dendritic Cells (pDCs) Phenotype . . . . . 179

11.4 Activation of pDCs . . . . . 180

11.5 pDCs: Bridging the Gap Between Innate  
and Adaptive Immunity. . . . . 183

11.6 pDCs and Human Diseases. . . . . 184

11.6.1 Role of pDCs in Human Infections. . . . . 184

11.6.2 Role of pDCs in Autoimmune Diseases . . . . . 185

11.6.3 Role of pDCs in Cancer . . . . . 186

11.7 Potential Therapies: Clinical Significance . . . . . 189

11.8 Concluding Remarks. . . . . 189

References . . . . . 190

<b>12 Cancer Immunoediting: Immunosurveillance, Immune Equilibrium, and Immune Escape</b>	<b>195</b>
Alka Bhatia and Yashwant Kumar	
12.1 Introduction	195
12.2 Cancer Immunoediting with Its Three Es: Reflection of the Dual Role of Immunity in Cancer	196
12.2.1 Immune Elimination: Evidences For and Against	197
12.2.2 The Equilibrium Phase: The Most Controversial and the Least Understood Phase	200
12.2.3 Immune Escape: The Best Studied Phase	201
12.3 Tumor Antigens and Cancer Immunoediting	203
12.4 The Tumor Microenvironment During Cancer Immunoediting	204
12.5 Clinical Relevance of the Immunoediting Process in Cancer	205
12.6 Concluding Remarks	206
<b>References</b>	<b>206</b>
<b>13 Apoptosis and Cancer</b>	<b>209</b>
Mei Lan Tan, Heng Kean Tan, and Tengku Sifzizul Tengku Muhammad	
13.1 Introduction	209
13.2 Mechanisms of Apoptosis	211
13.2.1 Extrinsic Apoptosis Pathway	212
13.2.2 Intrinsic Apoptosis Pathway	213
13.3 Apoptosis and Cancer	217
13.4 Apoptosis Signaling Pathways and Therapeutic Targets in Cancer	220
13.4.1 TRAIL (TRAIL Ligands, Monoclonal Antibodies Against TRAIL-R1 and TRAIL-R2)	220
13.4.2 Bcl-2 Family Proteins (BH3 Mimetics and Bcl-2 Antisense)	225
13.4.3 Proteasome Inhibitors	227
13.4.4 Inhibitor of Apoptosis Protein (IAP) Antagonists	229
13.5 Concluding Remarks	230
<b>References</b>	<b>231</b>
<b>14 Autophagy and Necroptosis in Cancer</b>	<b>243</b>
Mei Lan Tan, Heng Kean Tan, Ahmed Ismail Hassan Moad, and Tengku Sifzizul Tengku Muhammad	
14.1 Introduction	243
14.2 Autophagy and Cancer	247
14.3 Autophagy Signaling Pathways and Therapeutic Strategies in Cancer	249
14.3.1 mTOR Signaling Pathway Inhibitors	249
14.3.2 Pro-autophagics	250
14.3.3 Autophagy Inhibitors	251
14.4 Mechanisms of Necroptosis	252

14.5	Necroptosis and Possible Therapeutic Targets in Cancer. . . . .	260
14.6	Crosstalk in Apoptosis, Autophagy, and Necroptosis . . . . .	261
14.7	Future Directions. . . . .	263
14.8	Concluding Remarks. . . . .	263
	References . . . . .	264
<b>15</b>	<b>Prognostic Value of Innate and Adaptive Immunity in Cancers. . . . .</b>	<b>275</b>
	Fabio Grizzi, Giuseppe Di Caro, Federica Marchesi, and Luigi Laghi	
15.1	Introduction. . . . .	275
15.2	Immune Infiltration as a Major Player of the Tumor Microenvironment. . . . .	276
15.3	Cellular Players of the Innate Immunity in Cancer. . . . .	277
15.3.1	Tumor-Associated Macrophages (TAM). . . . .	277
15.3.2	Tumor-Associated Neutrophils (TAN) . . . . .	278
15.4	Cellular Players of the Adaptive Immunity in Cancer . . . . .	278
15.5	Prognostic Value of Innate and Adaptive Cells of the Immune System in Cancer . . . . .	279
15.6	Concluding Remarks. . . . .	281
	References . . . . .	281
<b>16</b>	<b>Epigenetics and microRNAs in Cancer . . . . .</b>	<b>285</b>
	Petra M. Wise, Kishore B. Challagundla, and Muller Fabbri	
16.1	Introduction. . . . .	285
16.2	MiRNAs Regulate Effectors of the Epigenetic Machinery. . . . .	286
16.3	MiRNAs Are Epigenetically Regulated in Several Types of Human Cancers . . . . .	289
16.4	Concluding Remarks. . . . .	291
	References. . . . .	292
<b>17</b>	<b>Immunogenetics of Cancer . . . . .</b>	<b>295</b>
	Armin Hirbod-Mobarakeh, Ali Akbar Amirzargar, Behrouz Nikbin, Mohammad Hossein Nicknam, Anton Kutikhin, and Nima Rezaei	
17.1	Introduction. . . . .	295
17.2	Cancers: Why Are There Different Faces? . . . . .	296
17.3	Immune Polymorphism. . . . .	296
17.4	Immunogenetics . . . . .	298
17.4.1	Background. . . . .	298
17.4.2	Immunogenetic Tools . . . . .	298
17.5	Immunogenetics: A Champion in Fighting the Losing Battle Against Cancer . . . . .	303
17.6	Human Leukocyte Antigen . . . . .	304
17.6.1	Background. . . . .	304
17.6.2	Genes Behind HLA. . . . .	304
17.6.3	From Polymorphisms to Clinic. . . . .	306

17.6.4	HLA Typing and HLA Association Studies:	
	Lessons from the Past . . . . .	308
17.6.5	Typing Methods. . . . .	311
17.6.6	Environmental Factors . . . . .	311
17.6.7	Linkage Disequilibrium . . . . .	311
17.7	The Cytokine Network . . . . .	312
17.7.1	Background . . . . .	312
17.7.2	Interleukin-1 Superfamily . . . . .	313
17.7.3	Interleukin-4 . . . . .	316
17.7.4	Interleukin-6 (IL-6). . . . .	317
17.7.5	Interleukin-8 . . . . .	318
17.7.6	Interleukin-10 . . . . .	319
17.7.7	Interleukin-12 . . . . .	323
17.7.8	Tumor Necrosis Factor- $\alpha$ and Lymphotoxin- $\alpha$ . . . . .	324
17.7.9	Interferon Gamma (IFN- $\gamma$ ) . . . . .	330
17.7.10	Transforming Growth Factor- $\beta$ (TGF- $\beta$ ). . . . .	330
17.8	Concluding Remarks. . . . .	333
	References . . . . .	333
18	<b>Primary Immunodeficiencies and Cancers . . . . .</b>	<b>343</b>
	Mona Hedayat, Waleed Al-Herz, Asghar Aghamohammadi, Kim E. Nichols, and Nima Rezaei	
18.1	Introduction. . . . .	344
18.2	Primary Antibody Deficiencies . . . . .	344
18.2.1	Common Variable Immunodeficiency. . . . .	344
18.2.2	X-Linked Agammaglobulinemia. . . . .	345
18.2.3	Selective IgA Deficiency. . . . .	346
18.3	Combined Immunodeficiencies. . . . .	346
18.3.1	IL-2-Inducible T-Cell Kinase Deficiency . . . . .	346
18.3.2	Purine Nucleoside Phosphorylase Deficiency. . . . .	347
18.3.3	Dedicator of Cytokinesis 8 Deficiency . . . . .	348
18.3.4	RHOH Deficiency . . . . .	349
18.3.5	MAGT1 Deficiency. . . . .	350
18.4	Phagocyte Defects. . . . .	351
18.4.1	Severe Congenital Neutropenia (Kostmann Syndrome) . . . . .	351
18.4.2	Shwachman–Diamond Syndrome. . . . .	352
18.4.3	GATA2 Deficiency . . . . .	352
18.5	Defects in Innate Immunity. . . . .	353
18.5.1	Epidermodysplasia Verruciformis . . . . .	353
18.5.2	Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome. . . . .	354
18.6	Diseases of Immune Dysregulation . . . . .	354
18.6.1	X-Linked Lymphoproliferative Disease . . . . .	354
18.7	Syndromes with Autoimmunity . . . . .	355
18.7.1	Autoimmune Lymphoproliferative Syndrome . . . . .	355
18.7.2	Autoimmune Polyendocrinopathy with Candidiasis and Ectodermal Dystrophy . . . . .	356



18.8 Other Well-Defined Immunodeficiencies . . . . .	356
18.8.1 DNA Repair Defects . . . . .	356
18.8.2 Signal Transducer and Activator of Transcription 3 Deficiency . . . . .	357
18.8.3 Wiskott–Aldrich Syndrome. . . . .	360
18.8.4 Chromosome 22q11.2 Deletion Syndrome. . . . .	361
18.9 Concluding Remarks. . . . .	361
References . . . . .	361
<b>19 Immunosenescence, Oxidative Stress, and Cancers . . . . .</b>	<b>377</b>
Tamas Fulop, Graham Pawelec, Gilles Dupuis, Rami Kotb, Bertrand Friguet, and Anis Larbi	
19.1 Introduction. . . . .	377
19.2 Immune System and Cancer . . . . .	378
19.2.1 Immunosenescence or Immune Aging . . . . .	378
19.2.2 Innate Immune System . . . . .	379
19.2.3 Adaptive Immune System. . . . .	383
19.2.4 Interaction Between Innate and Adaptive Immune Responses: Effect of Aging. . . . .	384
19.3 Inflammation Aging and Oxidative Stress . . . . .	385
19.4 Immunosenescence and Cancer . . . . .	387
19.5 Modulation . . . . .	388
19.6 Concluding Remarks. . . . .	388
References . . . . .	389
<b>20 Nutrition, Immunity, and Cancers . . . . .</b>	<b>395</b>
Hassan Abolhassani, Niyaz Mohammadzadeh Honarvar, Terezie T. Mosby, and Maryam Mahmoudi	
20.1 Introduction. . . . .	395
20.2 Role of Nutrition in Predisposition of Cancer from an Immunologic View . . . . .	396
20.2.1 Protein-Calorie Balance . . . . .	396
20.2.2 Essential Fatty Acids. . . . .	397
20.2.3 Antioxidants (Selenium, Vitamin E, and Vitamin C) . . . . .	397
20.2.4 Vitamin D . . . . .	397
20.2.5 Vitamin B6 . . . . .	397
20.2.6 Folate. . . . .	397
20.2.7 Calcium. . . . .	397
20.3 Aging as a Confounder of the Triangle of Nutrition, Immunity, and Cancer. . . . .	398
20.4 Role of Cancer in Predisposition to Malnutrition from an Immunologic View. . . . .	398
20.5 Role of Nutritional Support in Immune Restoration of Cancer Patients . . . . .	399
20.5.1 Arginine. . . . .	400
20.5.2 Glutamine . . . . .	400
20.5.3 Branched Chain Amino Acids. . . . .	400

20.5.4	Nucleotides, Long-Chain Omega-3 Polyunsaturated Fatty Acids, and Eicosapentaenoic Acid . . . . .	400
20.5.5	Fructooligosaccharides . . . . .	400
20.5.6	Bioactive Compounds . . . . .	400
20.5.7	Vitamins C and E . . . . .	400
20.5.8	Vitamin A . . . . .	401
20.6	Concluding Remarks . . . . .	401
	References . . . . .	401
<b>21</b>	<b>Allergies and Cancers . . . . .</b>	<b>407</b>
	Delia Rittmeyer and Axel Lorentz	
21.1	Introduction . . . . .	407
21.2	Molecular Mechanisms of Allergy . . . . .	408
21.3	Types of Allergic Diseases . . . . .	409
21.4	Molecular Basics of Carcinogenesis . . . . .	409
21.5	Types of Cancers . . . . .	410
21.6	Antitumor Immunity . . . . .	410
21.7	Relationship Between Allergies and Cancers in General . . . .	411
21.7.1	Cancers Positively Correlated with Allergies . . . . .	411
21.7.2	Tumor-Promoting Effects of Allergies . . . . .	412
21.7.3	Cancers Negatively Correlated with Allergies . . . . .	413
21.8	Tumor-Protecting Effects of Allergies . . . . .	414
21.9	Concluding Remarks . . . . .	415
	References . . . . .	416
<b>22</b>	<b>Cancer Immunology of Transmissible Cancers . . . . .</b>	<b>419</b>
	Katrina Marie Morris and Katherine Below	
22.1	Introduction . . . . .	419
22.2	Canine Transmissible Venereal Tumor . . . . .	420
22.2.1	Prevalence and Transmission . . . . .	420
22.2.2	Histology and Clonality . . . . .	420
22.2.3	Disease Progression . . . . .	421
22.2.4	Immunology . . . . .	421
22.3	Devil Facial Tumor Disease . . . . .	422
22.3.1	Prevalence and Appearance . . . . .	422
22.3.2	Transmission . . . . .	422
22.3.3	Immunology . . . . .	422
22.3.4	Do Devils Have an Impaired Immune System? . . . . .	423
22.3.5	Devils Have Low MHC Diversity . . . . .	423
22.3.6	Expression of Immunosuppressive Cytokines . . . . .	423
22.3.7	Regulation of Cell Surface MHC . . . . .	423
22.4	Comparison of DFTD and CTVT . . . . .	424
22.5	Evolution of Transmissible Cancers . . . . .	424
22.6	Transmissible Tumors as a Cancer Model . . . . .	425
22.7	Concluding Remarks . . . . .	426
	References . . . . .	426

<b>23</b>	<b>Envisioning the Application of Systems Biology in Cancer Immunology</b> . . . . .	<b>429</b>
	Julio Vera, Shailendra K. Gupta, Olaf Wolkenhauer, and Gerold Schuler	
23.1	Introduction . . . . .	429
23.1.1	The “Omics” Paradigm and the Use of Statistical Models . . . . .	430
23.1.2	Mathematical Modeling and Systems Theory: Dissecting the Complexity Emerging Out of the Structure of Biochemical Networks . . . . .	431
23.1.3	Bridging Biological Scales Through the Integration of Biological Data in Multi-scale Models . . . . .	431
23.2	One Step Further: Integrating the Different Perspectives of Systems Biology into a Unified Framework . . . . .	431
23.3	Does Cancer Immunology Need a Systems Biology Approach? . . . . .	434
23.4	A Quick View on Current Results . . . . .	434
23.4.1	Computational Biology, Bioinformatics, and High-Throughput Data Analysis Used in the Design of Immune Therapies for Cancer . . . . .	434
23.4.2	Mathematical Models Used in Basic Oncology Research . . . . .	440
23.5	Concluding Remarks . . . . .	446
	References . . . . .	447
<b>24</b>	<b>Principles of Immunological Diagnostic Tests for Cancers</b> . . . . .	<b>451</b>
	Amber C. Donahue and Yen-lin Peng	
24.1	Introduction . . . . .	451
24.2	Overview of Antibodies . . . . .	452
24.2.1	Monoclonal vs. Polyclonal Antibodies . . . . .	452
24.2.2	Antibody Fragments . . . . .	453
24.2.3	Reporter Labeling . . . . .	454
24.2.4	Primary and Secondary Antibodies . . . . .	454
24.3	Immunoprecipitation . . . . .	454
24.4	Immunoblotting . . . . .	455
24.5	Radioimmunoassays . . . . .	457
24.6	Enzymatic Immunoassays . . . . .	457
24.7	Immunocytochemical and Immunohistochemical Assays . . . . .	460
24.8	Flow Cytometry . . . . .	461
24.9	Bead-Based Assays . . . . .	464
24.10	Antibody Arrays . . . . .	465
24.11	Concluding Remarks . . . . .	468
	References . . . . .	468

**25 Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future** ..... 471  
Cécile Gouttefangeas, Steffen Walter, Marij J.P. Welters,  
Christian Ottensmeier, Sjoerd H. van der Burg,  
Cedrik M. Britten, and Cliburn Chan

25.1 Introduction ..... 471

25.2 Main Flow Cytometry Assays in Cancer Immunotherapy ..... 472

25.3 Panel Development and Quality Assurance ..... 474

25.4 Proficiency Programs Addressing Flow Cytometry Assays ..... 477

25.5 Structured Reporting of Immune Assay Experiments. .... 478

25.6 Organization of Immune Monitoring in Multicenter Trials ..... 479

25.7 Towards Automated Analysis ..... 480

25.8 New Methods and Technologies ..... 482

25.9 Concluding Remarks ..... 485

**References** ..... 486

**26 Immunohistochemistry of Cancers** ..... 491  
Alireza Ghanadan, Issa Jahanzad, and Ata Abbasi

26.1 Introduction ..... 492

26.2 Immunohistochemistry of Skin Tumors ..... 492

26.2.1 Markers of Normal Skin ..... 492

26.2.2 Epithelial Tumors ..... 494

26.2.3 Sweat Gland Tumors ..... 495

26.2.4 Trichogenic Tumors ..... 495

26.2.5 Sebaceous Tumors ..... 496

26.2.6 Melanocytic Tumors ..... 496

26.2.7 Prognostic Markers of Melanoma ..... 497

26.2.8 Specific Mesenchymal Tumors of the Skin ..... 497

26.3 Immunohistochemistry of Head and Neck Tumors ..... 499

26.3.1 Tumors of the Nasal Cavity and Paranasal Sinuses ..... 499

26.3.2 Tumors of the Larynx, Nasopharynx, and Oropharynx ..... 500

26.3.3 Tumors of the Salivary Glands ..... 501

26.3.4 Immunohistochemistry of Salivary Gland Tumors ..... 502

26.3.5 Tumors of Thyroid and Parathyroid Glands ..... 505

26.4 Immunohistochemistry of Lung Tumors ..... 505

26.4.1 Adenocarcinoma ..... 505

26.4.2 Mesothelioma ..... 506

26.5 Immunohistochemistry of Gastrointestinal Tumors ..... 507

26.5.1 Liver ..... 508

26.5.2 Esophagus ..... 509

26.5.3 Stomach ..... 509

26.5.4	Small Intestine.....	511
26.5.5	Colon.....	511
26.5.6	Anal.....	511
26.5.7	Appendix.....	511
26.5.8	Pancreas.....	511
26.5.9	Gastrointestinal Stromal Tumor.....	513
26.5.10	Neuroendocrine Carcinomas.....	513
26.6	Immunohistochemistry of the Urinary Tract.....	513
26.6.1	Kidney.....	513
26.6.2	Bladder.....	514
26.7	Immunohistochemistry of Female and Male Genital Tumors.....	516
26.7.1	Uterine Cervix.....	516
26.7.2	Vulva and Vagina.....	516
26.7.3	Uterine Corpus.....	516
26.7.4	Ovary.....	517
26.7.5	Breast.....	517
26.7.6	Prostate.....	520
26.7.7	Testis.....	521
26.8	Immunohistochemistry of Lymphoma.....	521
26.9	Immunohistochemistry of Soft Tissue and Bone Tumors.....	522
26.9.1	Epithelial Markers.....	523
26.9.2	Myogenic Markers.....	526
26.9.3	Nerve and Schwann Cell Markers.....	530
26.9.4	Endothelial Markers.....	530
26.9.5	Fibrohistiocytic Markers.....	531
26.9.6	Lipocytic Markers.....	533
26.9.7	Chondrocyte Markers.....	533
26.9.8	Osteogenic Markers.....	533
26.9.9	Unknown-Origin Soft Tissue Tumors.....	534
26.10	Immunohistochemistry of the Nervous System.....	534
26.10.1	Neuroepithelial Tumors.....	535
26.10.2	Non-neuroepithelial Tumors.....	536
26.10.3	Undifferentiated Tumors.....	538
26.10.4	Proliferative Markers.....	538
26.11	Immunohistochemistry of Pediatric Tumors.....	538
26.12	Immunosurveillance, Immune Editing, Immune Constant of Rejection, Immune Contexture, and Immune Scoring of Cancers.....	541
26.13	Concluding Remarks.....	545
	References.....	545
	<b>Index.....</b>	<b>561</b>